WWL70|cas:947669-91-2|西域试剂

WWL70,99.80%

产品编号：Bellancom-100337| CAS NO：947669-91-2| 分子式：C₂₇H₂₃N₃O₃| 分子量：437.49

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-100337	￥990.00	杭州北京（现货）
Bellancom-100337	￥1650.00	杭州北京（现货）
Bellancom-100337	￥3350.00	杭州北京（现货）
Bellancom-100337	￥5800.00	杭州北京（现货）
Bellancom-100337	￥9500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

WWL70

产品介绍

WWL70 是一个选择性的 α/β 水解酶结构域 6 (ABHD6) 抑制剂，其 IC₅₀ 值为 70 nM。

生物活性

WWL70 is a selective alpha/beta hydrolase domain 6 (ABHD6) inhibitor with an IC₅₀ of 70 nM.

体外研究

At 1 h after WWL70 (10 μM) treatment, 2-Arachidonoylglycerol (2-AG) is increased by 20% compare to untreated cells. At either 1 or 10 μM, WWL70 completely blocks the lipopolysaccharide (LPS)-induced increase of PGE₂. The enhanced mRNA expression of mPGES-1 and mPGES-2 by LPS is also reduced by WWL70. The IC₅₀ of WWL70 to inhibit the PGE₂ biosynthesis is about 100 nM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Although post-treatment with WWL70 at 5 mg/kg does not have any effect, treatment with WWL70 at 10 mg/kg improves the performance significantly. WWL70 treatment improves motor coordination of traumatic brain injury (TBI) mice in a concentration dependent manner. The latency to fall in animals treated with WWL70 at 5 mg/kg increases from 74.92±4.8 to 99.57±5.21 on day 3 (p<0.01) and from 87.32±4.42 to 100.14±3.56 on day 7 (p<0.05) post-injury when compare with the vehicle-TBI groups. At 10 mg/kg, WWL70 treatment improves motor coordination starting on day 1 post-injury. WWL70 treatment completely restores the ability of TBI mice to continuously alternate arms during Y maze exploration (69.67±4.98 %).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : 17.33 mg/mL (39.61 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2858 mL	11.4288 mL	22.8577 mL
5 mM	0.4572 mL	2.2858 mL	4.5715 mL
10 mM	0.2286 mL	1.1429 mL	2.2858 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 2.5 mg/mL (5.71 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (5.71 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% saline
Solubility: 2.2 mg/mL (5.03 mM); Suspended solution; Need ultrasonic